EN PL
PRACA ORYGINALNA
Specyficzne przeciwciała przeciwjądrowe u pacjentów z zespołem Raynauda
 
Więcej
Ukryj
 
Data publikacji online: 20-12-2010
 
 
Reumatologia 2010;48(6):391-395
 
SŁOWA KLUCZOWE
STRESZCZENIE
Objaw Raynauda pojawia się jako wynik ekspozycji na niskie temperatury oraz stres. Jako wtórny objaw współistnieje z układowymi chorobami tkanki łącznej, takimi jak: twardzina układowa, toczeń rumieniowaty układowy, zapalenie skórno-mięśniowe. Ocena obecności autoprzeciwciał u chorych z objawem Raynauda jest metodą nieinwazyjną, nie jest obarczona ryzykiem powikłań i może być użyteczna w diagnozowaniu chorych z objawem Raynauda. W pracy przedstawiono wyniki obserwacji klinicznej i badań laboratoryjnych grupy 76 pacjentów z objawem Raynauda.
 
REFERENCJE (25)
1.
Le Roy EC, Medsger TA Jr. Raynaud’s phenomenon: a proposal for classification. Clin Exp Rheumatol 1992; 10: 485-488.  .
 
2.
Silman A, Holligan S, Brennan P, Maddison P. Prevalence of symptom Raynaud’s phenomenon in general practice. Br Med J 1990; 301: 590-592.  .
 
3.
Maricq HR, Carpentier PH, Weinrich MC, et al. Geographic variation in prevalence of symptom Raynaud’s phenomenon: a 5 region comparision. J Rheumatol 1997; 24: 879-889.  .
 
4.
Silman AJ, Black CM, Welsh KI. Epidemiology, demographics, genetics. In: Systemic sclerosis, Clements PJ, Furst DE (eds). Williams&Wilkins, Baltimore 1996; 2: 23-50.  .
 
5.
Kallenberg CG. Early detection of connective tissue disease in patients with Raynaud’s phenomenon. Rheum Dis Clin North Am 1990; 16: 11-30.  .
 
6.
Spencer-Green G. Outcomes in primary Raynaud’s phenomenon: a meta-analysis and the frequency, rates and predictors of transition to secondary disease. Arch Intern Med 1998; 158: 595-600.  .
 
7.
Carpentier PH, Maricq HR. Microvasculature in systemic sclerosis. Rheum Dis Clin North Am 1990; 16: 75-91.  .
 
8.
Boyd RL, Wilson TJ, Van De Water J, et al. Selective abnormalities in the thymic microenvironment associated with avian scleroderma, an inherited fibrotic disease of L200 chickens. J Autoimmun 1991; 4: 369-380.  .
 
9.
Furst DE. The endothelium in the pathogenesis of systemic sclerosis: is it primary or secondary? [editorial]. J Mal Vasc 1999; 24: 95-98. .
 
10.
Clements PhJ, Furst DE (eds). Systemic sclerosis (textbook). Williams&Wilkins, Baltimore 1966. .
 
11.
Nelson JL, Furst DE, Maloney S, et al. Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet 1998; 351: 559-562. .
 
12.
LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-1576. .
 
13.
Herrick AL. Patogenesis of Raynaud’s phenomenon. Rheumatology 2005; 44: 587-596. .
 
14.
Systemic sclerosis: current pathogenetic concepts and future prospects for targeted therapy. Lancet 1996; 347: 1453-1458. .
 
15.
Spencer-Green G. Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med 1998; 158: 595-600. .
 
16.
Kallenberg CG. Overlapping syndromes, undifferentiated connective tissue disease, other fibrosing conditions. Curr Opin Rheumatol 1995; 7: 568-573. .
 
17.
Chen ZY, Silver RM, Ainsworth SK, et al. Association between fluorescent antinuclear antibodies, capillary patterns, and clinical features in scleroderma spectrum disorders. Am J Med 1984; 77: 812-822. .
 
18.
Weiner ES, Hildebrandt S, Senecal JL, et al. Prognostic significance of anticentromere antibodies and anti- topoisomerase I antibodies in Raynaud's disease. A prospective study. Arthritis Rheum 1991; 34: 68-77. .
 
19.
Sarkozi J, Bookman AA, Lee P, et al. Significance of anticentromere antibody in idiopathic Raynaud's syndrome. Am J Med 1987; 83: 893-898. .
 
20.
Bulpitt KJ, Clements PJ, Lachenbruch PA, et al. Early differentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis). Ann Intern Med 1993; 118: 602-609. .
 
21.
Giordano M, Valentini G, Migliaresi S, et al. Different antibody patterns and different prognoses in patients with various extent of skin sclerosis. J Rheumatol 1986; 13: 911-916. .
 
22.
Bryan C, Knight C, Black CM, et al. Prediction of five-year survival following presentation with scleroderma. Develop­ment of a simple model using three disease factors at first visit. Arthritis Rheum 1999; 42: 2660-2665. .
 
23.
Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-1533. .
 
24.
Medsger TA Jr, Masi AT, Rodnan GP, et al. Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 1971; 75: 369-376. .
 
25.
Altman RD, Medsger TA Jr, Bloch DA, et al. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991; 34: 403-413.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top